Posts

Sanofi floats flu shot marketing pledges to pacify EU antitrust probe

on

Merck Posts Encouraging Phase 3 Ulcerative Colitis Data But Roche Challenge Looms

on

AstraZeneca Signs Three-Year Agentic AI Licensing Deal with Owkin for K Pro Platform

on

Novo Nordisk Q1: Pills, Pricing, Payments, Pressure

on

Zealand Pharma and Roche's Obesity Drug Development and Clinical Progress

on

Novo Nordisk CEO and Board Leadership Step Down Amid Market Pressures; New Board to Prioritize Faster Decision-Making

on

Novartis Receives FDA Approval for Rhapsido: First Oral BTK Inhibitor for Chronic Hives

on

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

on

Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review

on

Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance

on

Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly's Pill Shows Modest Results

on

Novo Nordisk's Pipeline Cull Prompts Hopes of Strategic Shift

on

Pfizer's Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

on

Novo Nordisk's Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

on

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

on

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

on

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

on

A closer look at pharmas top patent losses in 2025

on

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

on

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

on